Clinical Trial Results:
            A phase III, randomized, multi-center, open-label, 12 to 14 months extension study to evaluate the safety and tolerability of SPD476 (mesalazine) give once daily vs. twice daily for the maintenance of ulcerative colitis in remission. 
    
|     Summary | |
|     EudraCT number | 2004-000734-36 | 
|     Trial protocol | CZ | 
|     Global completion date | 
                                    13 Mar 2006
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    21 Sep 2019
                             | 
|     First version publication date | 
                                    28 Jun 2015
                             | 
|     Other versions | |
|     Summary report(s) | SPD476-303 CSR Synopsis Redaction | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
